logo

For the Inventor, By the Inventor

Edingen-Neckarhausen, Germany

Günther Metz

This inventor holds 10 USPTO granted patents. Top assignees: Esperion Therapeutics, Inc., Other. Active years: 2001-2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Günther Metz. Retrieved from https://idiyas.com/inventor/ganduumlnther-metz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10

% Patents Active = 90.0

Average Co-Inventor Count = 5.8

ph-index = 10

Forward Citations = 383(Granted Patents)


Location History:

  • Edingen-Neckarhausen, DE (2001 - 2004)
  • Edingen-Necharhausen, DE (2004)

Company Filing History:

goldMedal2 out of 60 
 
Esperion Therapeutics, Inc.
 patents
silverMedal8 out of 834,513 
Other
 patents

Years Active: 2001-2004

Loading Chart...
10 patents (USPTO):Explore Patents
1. 6753313 - Multimeric Apoa-I agonist compounds (2004-06-22),
2. 6734169 - Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders (2004-05-11),
3. 6716816 - Multimeric Apo A-I agonist compounds (2004-04-06),
4. 6630450 - Method of treating dyslipidemia (2003-10-07),
5. 6602854 - Branched multimeric Apo A-I agonist compounds (2003-08-05),
6. 6573239 - Apolipoprotein A-I agonist compounds (2003-06-03),
7. 6518412 - Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders (2003-02-11),
8. 6376464 - Lipid complexes of APO A-1 agonist compounds (2002-04-23),
9. 6329341 - Method of treating septic shock (2001-12-11),
10. 6265377 - Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders (2001-07-24),

Sure, I can help with that! Here is an article about inventor Günther Metz:

Title: Unveiling the Remarkable Innovations of Günther Metz

Introduction:

Günther Metz, a brilliant inventor hailing from Edingen-Neckarhausen, DE, has made significant contributions to the field of dyslipidemia treatment with his groundbreaking patents.

Latest Patents:

1. Multimeric Apoa-I Agonist Compounds: Metz's invention introduces peptides and peptide analogues that replicate the structural and pharmacological characteristics of human ApoA-I, offering novel solutions for dyslipidemia-related disorders.

2. Apolipoprotein A-I Agonists for Dyslipidemic Disorders: Another innovation by Metz, presenting peptides and peptide analogues that mimic human ApoA-I, providing effective treatments for various dyslipidemic conditions.

Career Highlights:

Throughout his career, Günther Metz has accumulated an impressive portfolio of 10 patents, establishing himself as a leading figure in the field of dyslipidemia research and treatment.

Collaborations:

Metz has collaborated with esteemed professionals in his field, including the likes of Jean-Louis Henri Dasseux and Renate Sekul, fostering a collaborative spirit that has led to groundbreaking advancements in dyslipidemia management.

Conclusion:

In conclusion, Günther Metz's innovative work in dyslipidemia treatment underscores his remarkable talent and dedication to improving healthcare outcomes. His patents stand as a testament to his relentless pursuit of excellence in the field of medical research, shaping the landscape of dyslipidemia management for years to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…